Indeed a very good spot.Masked data from patients that have...

Indeed a very good spot.

Masked data from patients that have completed the week 52 visit in the ongoing Phase 3 clinical trials show greater mean BCVA increases from baseline than results with standard of care anti-VEGF-A monotherapy from Opthea’s Phase 2b study.

Trying to put some numbers around:

Mean BCVA increase from baseline in…

… P2b from 119 patients in the standard of care anti-VEGF-A monotherapy sham arm: 10.8 letters
… P2b from all 240 patients in both the 2.0 mg and the sham arm: 12.5 letters
… P2b from 121 patients in the 2.0 mg arm: 14.2 letters

… P3 from all patients that have completed 52 w in the 2.0 mg and the different sham arms: >10.8 letters

So, „>10.8“ has to be compared to „12.5“.

The two potential alternatives that would be positive:
Either „>10.8 for all patients in P3“ means a number really much greater than 10.8, e.g. 13.0 oder even 15.0.
Or the two sham arms in P3 fare much worse than the 10.8 sham in P2b, e.g. 9.0 or even 8.0.